Ironwood Pharmaceuticals Inc. of Cambridge and Forest Laboratories Inc. said in a Monday press release that Ironwood’s new drug for irritable bowel syndrome with constipation is now available in the United States.
The drug is being marketed in the US under the brand name Linzess. It was approved by the Food and Drug Administration earlier this year as a treatment for adults suffering from irritable bowel syndrome with constipation. (Linzess is a trade name for linaclotide.)
It has been estimated that irritable bowel syndrome afflicts 30 million to 40 million Americans. Partly as a result, some stock analysts project that the Ironwood drug can attain blockbuster status — ringing up sales of more than $1 billion a year worldwide — within a decade, a recent Globe story noted.